NEW YORK (Thomson Financial) - Cell Genesys Inc. Friday said data from a
completed Phase I/II clinical trial of GVAX immunotherapy for prostate cancer
indicates the treatment results in a statistically significant increase in
median prostate-specific antigen doubling time, as well as the formation of
prostate cancer-associated antibodies in 79% of patients.
The trial studied GVAX in men with recurrent prostate cancer who hadn't yet
received treatment with hormone replacement therapy following relapse after
prostate cancer surgery and/or radiation therapy.
The company is now planning a larger, randomized study to further examine
the potential application of GVAX in this patient population, and is currently
conducting a study evaluating the treatment in combination with docetaxel as a
pre-operative therapy in men with high-risk prostate cancer.
Cell Genesys shares rose 3.6% to $3.20 in premarket trading.
Christie Rizk
cr/jw
COPYRIGHT
Copyright Thomson Financial News Limited 2007. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|